Biotech News

Cytokinetics to Announce Third Quarter Results on November 4, 2026

Cytokinetics (CYTK)Cytokinetics2026-10-21 20:00 ESTEarnings

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates.

Related news

CYTKCytokinetics2026-07-23 20:00 EST

Cytokinetics to Announce Second Quarter Results on August 6, 2026

CYTKCytokinetics2026-08-06 20:00 EST

Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update

View all latest news

Cytokinetics

Muscle Biology Specialization Cytokinetics develops and commercializes medicines that modulate muscle function. Its portfolio is centered on cardiac muscle biology and diseases in which altered contractility contributes directly to symptoms and clinical outcomes. MYQORZO in Obstructive HCM MYQORZO, or aficamten, is a cardiac myosin...

Recent company news

CYTKCytokinetics2026-11-03 21:00 EST

Cytokinetics to Participate in November Investor Conferences

CYTKCytokinetics2026-11-02 12:30 EST

Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026

CYTKCytokinetics2026-10-21 20:00 EST

Cytokinetics to Announce Third Quarter Results on November 4, 2026

CYTKCytokinetics2026-10-19 20:00 EST

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CYTKCytokinetics2026-10-19 11:30 EST

Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Stock data

Close: 55.55 USD
Market cap: 9.63B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States